HIGH-RISK MI PATIENTS DERIVE GREATEST ABSOLUTE BENEFIT FROM PRIMARY PERCUTANEOUS CORONARY INTERVENTION: RESULTS FROM THE PRIMARY CORONARY ANGIOPLASTY TRIALIST COLLABORATION  by De Boer, Sanneke P. et al.
A105.E983
JACC March 9, 2010
Volume 55, issue 10A
 MYOCARDIAL ISCHEMIA AND INFARCTION 
HIGH-RISK MI PATIENTS DERIVE GREATEST ABSOLUTE BENEFIT FROM PRIMARY PERCUTANEOUS 
CORONARY INTERVENTION: RESULTS FROM THE PRIMARY CORONARY ANGIOPLASTY TRIALIST 
COLLABORATION
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Sunday, March 14, 2010, 9:30 a.m.-10:30 a.m.
Session Title: Acute Myocardial Infarction--PCI Strategies
Abstract Category: Acute Myocardial Infarction--Therapy
Presentation Number: 1051-315
Authors: Sanneke P. De Boer, Liz Barnes, Cyntia W. Westerhout, John Simes, Christopher B. Granger, Felix Zijlstra, Eric Boersma, ErasmusMC, 
Rotterdam, The Netherlands
Background: Meta-analyses of randomized trials showed that primary percutaneous coronary intervention (PPCI) results in lower mortality than 
fibrinolytic (FL) therapy in myocardial infarction (MI) patients. We investigated which (categories of) MI patients would benefit most of the strategy of 
PPCI, and thus have lowest numbers needed to treat (NNTs).
Methods: Twenty-five randomized trials (n=7743) that evaluated the efficacy and safety of PPCI vs. FL were identified published between 1990 
and 2002. Individual patient data were obtained from 22 trials (n=6763). A risk score was developed by multivariable logistic regression to estimate 
the probability of 30-day mortality in individuals. Patients were then divided in quartiles according to risk. Subsequent analyses were performed to 
evaluate if treatment effect was modified by baseline risk.
Results: Overall, 446 (6.6%) patients died within 30 days after randomization. The mortality risk score contained sex, age, MI location, prior 
MI, diabetes, systolic blood pressure, heart rate and time to treatment. The corresponding C-index was 0.75, and the Hosmer-Lemeshow test was 
non-significant (p-value 0.90), reflecting adequate discrimination and calibration. Patients randomized to PPCI had lower mortality than those 
randomized to FL (5.3% versus 7.9% events; adjusted OR 0.61; p<0.001). The risk score * allocated treatment interaction term had no contribution 
(p<0.001) to the model indicating that the relative mortality reduction by PPCI was not modified by baseline mortality risk. In contrast the absolute 
risk reduction was strongly related with baseline risk: the NNT was 294 in the lowest quartile of estimated risk compared to 15 in the highest 
quartile.
Conclusion: Although PPCI is consistently associated with a reduction in mortality, irrespective of baseline characteristics, the absolute benefit of 
PPCI is greater in higher risk patients.
